新华制药：全资子公司取得药品注册证书，产品名称为“熊去氧胆酸胶囊”

Group 1 - The core point of the article is that Xinhua Pharmaceutical has received approval for the registration of Ursodeoxycholic Acid Capsules from the National Medical Products Administration [1] - Xinhua Pharmaceutical's revenue composition for the first half of 2025 is as follows: 44.36% from chemical drug formulation manufacturing, 32.11% from chemical raw material manufacturing, and 23.53% from pharmaceutical intermediates and others [1] - As of the report, Xinhua Pharmaceutical has a market capitalization of 11.6 billion yuan [1]